Condition

Generalized Myasthenia Gravis clinical trials and research

• 18Clinical trials
• 33Countries

Newest Generalized Myasthenia Gravis clinical trials

All recruiting trials (18)

• SHR-2173 injection added to standard care for generalized myasthenia gravis

  This Phase 2 trial tests whether SHR-2173 added to usual treatment helps adults with generalized myasthenia gravis more than a placebo add-on.

  Recruiting at 2 sites Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Changsha, Hunan and 1 other locations · NCT07622342

• Ravulizumab for Generalized Myasthenia Gravis in Chinese Adults

  This trial tests ravulizumab in Chinese adults with generalized myasthenia gravis to see if it helps symptoms while checking safety and how the drug behaves in the body.

  Recruiting at 8 sites Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07596784

• Tracking Real-Life Myasthenia Gravis Symptoms in Patients on Rozanolixizumab

  This observational study follows adults with generalized myasthenia gravis who are treated with Rozanolixizumab to see how their symptoms and fatigue change in real life.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice, Alpes-maritimes and 10 other locations · NCT07570589

• ADAPT Forward master protocol testing multiple regimens for generalized myasthenia gravis

  This platform tests several drug regimens, including efgartigimod IV and empasiprubart IV, in adults with generalized myasthenia gravis to find safer and more effective treatment combinations.

  Recruiting at 37 sites argenx · Carlsbad, California and 36 other locations · NCT07294170

• Adding empasiprubart to efgartigimod for AChR-antibody positive generalized myasthenia gravis

  This trial will test whether adding empasiprubart to efgartigimod infusions helps people with AChR-antibody positive generalized myasthenia gravis who have only had a partial response to efgartigimod.

  Recruiting at 33 sites Phase 2 argenx · Carlsbad, California and 32 other locations · NCT07284420

• Oral steroid tapering for adults with generalized myasthenia gravis on ravulizumab.

  This study will try a predefined prednisone taper to see if adults with generalized myasthenia gravis on ravulizumab can safely reduce their daily steroid dose.

  Recruiting Phase 4 Alexion Pharmaceuticals, Inc. · Chicago, Illinois and 11 other locations · NCT07221838

• Cizutamig for adults with generalized myasthenia gravis

  This will test whether cizutamig is safe and shows early benefit for adults with generalized myasthenia gravis who haven't responded to standard treatments.

  Recruiting at 10 sites Phase 1 Candid Therapeutics · Fuzhou, Fujian and 9 other locations · NCT07215650

• IMVT-1402 for adults with mild to severe generalized myasthenia gravis.

  This trial will test whether IMVT-1402 helps adults with mild to severe generalized myasthenia gravis improve symptoms and daily function compared with placebo.

  Recruiting at 88 sites Phase 3 Immunovant Sciences GmbH · Huntsville, Alabama and 87 other locations · NCT07039916

• Inebilizumab in children with generalized myasthenia gravis: drug handling and tolerability

  This trial will test inebilizumab in children aged 2 to 17 with generalized myasthenia gravis to see how the drug is processed in the body and whether it is safe and well tolerated.

  Recruiting at 14 sites Phase 2 Amgen · Chicago, Illinois and 13 other locations · NCT06987539

• Early ravulizumab for anti‑AChR antibody–positive generalized myasthenia gravis

  This study tests whether starting ravulizumab early can improve daily muscle weakness and function for people with anti‑AChR antibody–positive generalized myasthenia gravis.

  Recruiting at 9 sites Alexion Pharmaceuticals, Inc. · Bergamo and 22 other locations · NCT06967480

• Evaluating gefurulimab for treating pediatric patients with generalized myasthenia gravis

  This study is testing a new drug called gefurulimab to see if it can help children and teens with generalized myasthenia gravis feel better.

  Recruiting at 11 sites Phase 3 Alexion Pharmaceuticals, Inc. · Washington D.C., District of Columbia and 12 other locations · NCT06607627

• New oral cladribine formulation for treating generalized myasthenia gravis

  This study is testing a new pill for people with generalized myasthenia gravis to see if it helps them feel better compared to a sugar pill.

  Recruiting at 150 sites Phase 3 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Phoenix, Arizona and 153 other locations · NCT06463587

• Evaluating B007 for treating generalized myasthenia gravis

  This study is testing a new treatment called B007 to see if it can help people with generalized myasthenia gravis feel better.

  Recruiting at 18 sites Phase 2/3 Shanghai Jiaolian Drug Research and Development Co., Ltd · Beijing and 17 other locations · NCT06447597

• Efgartigimod PH20 SC treatment for children with generalized Myasthenia Gravis

  This study is testing a new injection treatment for children with generalized Myasthenia Gravis to see how well it works and what the right dosage is.

  Recruiting at 19 sites Phase 2/3 argenx · Charlotte, North Carolina and 21 other locations · NCT06392386

• Anti-CD19 CAR T-Cell Therapy for Refractory Myasthenia Gravis

  This study is testing a new CAR T-cell therapy to see if it can help adults with tough-to-treat myasthenia gravis feel better.

  Recruiting at 22 sites Phase 2/3 Kyverna Therapeutics · Los Angeles, California and 21 other locations · NCT06193889

• Effects of electrical muscle stimulation exercise on adults with Myasthenia Gravis

  This study is testing if whole-body electrical muscle stimulation exercise can help adults with Myasthenia Gravis feel less tired and improve their muscle function.

  Recruiting at 2 sites University of Missouri-Columbia · Fairway, Kansas and 1 other locations · NCT06064695

• Evaluating Zilucoplan for Pediatric Myasthenia Gravis

  This study is testing a new medication called zilucoplan to see how it works and if it's safe for children aged 2 to 18 with generalized myasthenia gravis.

  Recruiting at 5 sites Phase 2/3 UCB Pharma · Chicago, Illinois and 8 other locations · NCT06055959

• Registry for patients with generalized myasthenia gravis treated with C5 inhibitors

  This study is collecting long-term information from people with generalized myasthenia gravis who are being treated with C5 inhibitors to see how well these treatments work and if they are safe.

  Recruiting at 51 sites Alexion Pharmaceuticals, Inc. · Birmingham, Alabama and 50 other locations · NCT04202341

Related topics

Quick answers

How many Generalized Myasthenia Gravis clinical trials are recruiting right now?

18, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 33 countries. The most sites are in United States (12 trials), Italy (10 trials), Germany (8 trials), Poland (8 trials), Spain (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2/3: 4, Phase 3: 4, Phase 2: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →